Research · 10 min read
What Body Composition Means, and Why a Scale That Claims It Is Not the Trial Method
The labels state that more of the loss is fat than lean tissue. Across six of these prescribing documents, not one names the instrument that showed it — and the guidance behind them names exactly which instruments count.
Key takeaways
- Body composition is the split of total weight into fat and lean tissue; a scale reports only the total.
- FDA's draft guidance asks for baseline and follow-up measurement by DXA or a suitable alternative in a representative sample of trial subjects, as a check that the loss was primarily fat.
- It states that in pharmacological trials fat has typically accounted for 60 to 90 percent of weight reduction, and that the accompanying lean loss has not been considered adverse.
- It also explains that people with obesity carry greater lean mass, higher bone density, greater organ weight and more total body water than lean individuals.
- The labels state the conclusion — more fat than lean loss — and across six of these prescribing documents none names DXA, impedance, or the phrase body composition, with positive controls confirming the search worked.
- Consumer devices that report a fat percentage measure electrical impedance, which the guidance says varies with hydration status.
- A body composition efficacy claim is treated by the guidance as a separate undertaking requiring early consultation with the agency.
Answer first: composition is the split, and weight cannot see it
A scale reports one number for several different things at once: fat, muscle, bone, water, and the current contents of a digestive tract. Body composition is the question of how that total divides.
The distinction matters in weight loss because the two parts of the split have different consequences. Every method of losing weight — diet, surgery, or medication — takes some of both. The FDA's draft guidance on weight-reduction drugs states this directly: loss of lean mass is observed after weight reduction in patients with obesity or overweight regardless of intervention type.
So the useful question was never whether lean tissue moves. It is how much, measured how, and by whom.
What the guidance actually asks a trial to do
The requirement is more specific than most coverage of this topic suggests, and it is worth quoting in structure.
The guidance asks for a check that weight reduction was caused primarily by a reduction in fat content and not lean body mass. A representative sample of trial subjects, it says, should have a baseline and follow-up measurement of body composition by dual x-ray absorptiometry — abbreviated DXA — or a suitable alternative. In pediatric trials it repeats the instruction without the representative-sample qualifier: baseline and follow-up body composition by DXA or suitable alternative should be obtained in pediatric subjects.
Notice what that is and is not. It is a safety and interpretation check on a subset of participants, run to confirm that the weight coming off is mostly fat. It is not the trial's efficacy endpoint. The guidance draws that line itself. A sponsor seeking an efficacy claim about changes in body composition would need to consult the agency early in development, to align on the clinical condition being treated. The trial design for such a claim, it adds, is beyond the scope of the document.
In other words, measuring composition to check a result and making a claim about composition are two different regulatory activities. Only the first is routine.
The number the guidance puts on it
The guidance supplies the figure that most of this argument turns on. In pharmacological trials, reduction of fat mass has typically accounted for 60 to 90 percent of weight reduction, and the accompanying reduction in lean mass has not been considered adverse.
It also explains why lean loss in this population is not the same event as lean loss in a lean person. Patients with obesity or overweight have greater lean mass than lean individuals. That includes greater muscle mass, higher bone density, and increased organ weight — it names liver, kidneys, and pancreas. It also includes greater absolute total body water, despite a lower percentage of body water. A larger body is carrying more of everything, not only more fat, so some of what leaves during weight loss is structure that was supporting the larger body.
That is the regulator's framing, published in a document written for the companies running these trials. It is neither a dismissal of the concern nor an alarm about it.
The labels state the conclusion and never name the instrument
Here is a small finding with a large consequence for how you read a product page.
The pharmacodynamics sections of the three weight products describe the same profile in nearly the same words. The drug lowers body weight with greater fat mass loss than lean mass loss, decreases calorie intake, and its effects are likely mediated by appetite. That statement is a claim about composition.
Six prescribing documents were read for this article: the two approved weight products, the two injectable diabetes products, the combined oral semaglutide label, and the newer oral weight product. A search of the full parsed text of all six found no occurrence of DXA, DEXA, absorptiometry, bioelectrical impedance, plain impedance, or the phrase body composition. Zero, on all six. The same pass found fat mass and lean mass twice each in three of those labels, and the word placebo between 134 and 514 times in each. So the ruler was working, and the documents were the ones they claimed to be.
The conclusion travels. The method does not. Anyone reading a label learns that more fat than lean tissue was lost, and learns nothing about how that was established, in whom, or how many people were measured.
Why a household scale is not doing what the trial did
Consumer scales that print a body fat percentage work by sending a small current through the body and measuring the resistance it meets, then running that resistance through an estimating equation. The measured quantity is electrical impedance. Everything past that — the fat percentage, the muscle number, the water figure — is a calculation on top of it.
The guidance addresses that measurement class in one sentence, in its list of alternatives to the body mass index. Bioelectrical impedance may vary depending on the hydration status of the individual. Because water conducts, how hydrated a body is at the moment of measurement changes the number the device is actually measuring, which changes everything the equation derives from it.
The guidance is similarly brief about the other cheap option. Assessment of skinfold thickness is operator dependent and has relatively poor reproducibility — meaning two people pinching the same body get different answers, and the same person on two days may too.
About imaging it is more positive and more cautious at once. Imaging modalities such as DXA or magnetic resonance imaging may provide more precise measures of body fat, but they are expensive and require the use of multiple blinded central readers for implementation in a trial. And then a warning that cuts the other way: trial results based on imaging changes may not be generalizable to the clinical care of patients.
So even the method the guidance names for trials comes with an asterisk about how well it transfers out of one. That is a long way from a bathroom scale reporting a fat percentage to one decimal place.
What a consistent measurement is still good for
None of the above makes a home measurement worthless, and the distinction is between accuracy and consistency.
Accuracy is whether a number matches the true value. On that, the guidance's objection to impedance stands: a reading that shifts with hydration is not reliably reporting the underlying quantity. Consistency is whether the same method, in the same conditions, moves in the same direction as the thing it is estimating. A device can be poor at the first and still informative about the second. That is why the useful discipline with any of these tools is to keep the method and the conditions identical between readings, and to watch the direction rather than the decimal.
What a home device cannot do is settle a disagreement with a trial. When a program advertises a body composition result, the questions are which instrument produced it, on how many people, and against what comparison. A trial answers all three in a protocol. A scale answers none of them, and the labels in this class, as printed, do not answer the first one either.
How to read a composition claim on a program page
Four questions cover most of it.
What was measured, and with what. A claim built on impedance is built on a quantity the FDA guidance describes as varying with hydration. A claim built on imaging should say so.
Compared with what. Every method of losing weight loses some lean tissue, so a claim that a program preserves lean mass is a comparative claim and needs a comparator to mean anything.
In how many people. The guidance asks for a representative sample of trial subjects, not everyone, which tells you that even in a rigorous trial this measurement is usually made on a subset.
And is it an efficacy claim. The guidance treats a body composition efficacy claim as something requiring early consultation with the agency and a defined clinical condition. A product page asserting one has taken a step the guidance describes as a separate regulatory undertaking, and none of the six labels read here carries such a claim in its own text.
Sources
- Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction — Guidance for Industry (Draft Guidance)The statement that lean mass loss occurs after weight reduction regardless of intervention type; the description of greater lean mass, muscle mass, bone density, organ weight and total body water in patients with obesity; the figure that fat mass has typically accounted for 60 to 90 percent of weight reduction in pharmacological trials with the accompanying lean reduction not considered adverse; the recommendation of baseline and follow-up body composition measurement by DXA or a suitable alternative in a representative sample of subjects, and in pediatric subjects; the statement that a body composition efficacy claim requires early consultation with the agency and is beyond the document's scope; and the assessments that skinfold thickness is operator dependent with poor reproducibility, that bioelectrical impedance may vary with hydration status, and that imaging is more precise but expensive, requires multiple blinded central readers, and may not generalize to clinical care.
- ZEPBOUND (tirzepatide) injection — full prescribing information, Section 12.2 PharmacodynamicsThe pharmacodynamic statement that the drug lowers body weight with greater fat mass loss than lean mass loss and decreases calorie intake with effects likely mediated by appetite, and the absence from the full label text of any named body composition measurement method.
- WEGOVY (semaglutide) injection and tablet — full prescribing information, Section 12.2 PharmacodynamicsThe matching pharmacodynamic statement on greater fat mass loss than lean mass loss, and the absence from the full label text of any named body composition measurement method.
- FOUNDAYO (orforglipron) tablet, film coated — full prescribing information, Section 12.2 PharmacodynamicsThe third instance of the same pharmacodynamic statement on greater fat mass loss than lean mass loss with reduced food intake mediated by decreased appetite, and the absence from the full label text of any named body composition measurement method.
Frequently asked questions
What does body composition mean?
It is the breakdown of total body weight into its parts, chiefly fat and lean tissue. A scale reports the total only, so it cannot distinguish a change in one part from a change in another.
How much of the weight lost in these trials was fat?
FDA's draft guidance states that in pharmacological trials, reduction of fat mass has typically accounted for 60 to 90 percent of weight reduction, and that the accompanying reduction in lean mass has not been considered adverse. That is a general statement about the trial literature in this guidance, not a figure attached to any single product.
What method does the FDA expect trials to use?
Dual x-ray absorptiometry, abbreviated DXA, or a suitable alternative, taken at baseline and follow-up in a representative sample of trial subjects, to confirm that weight reduction was caused primarily by a reduction in fat rather than lean body mass. In pediatric trials it asks for the same measurement in the subjects generally.
Do the labels say which instrument was used?
Not in the six prescribing documents read for this article. The pharmacodynamics sections state that the drugs lower body weight with greater fat mass loss than lean mass loss. A full-text search of all six found no occurrence of DXA, absorptiometry, impedance, or the phrase body composition, while control terms in the same search returned the expected hits.
Is a smart scale measuring my body fat?
It is measuring electrical impedance and calculating a fat estimate from it. The FDA guidance's note on that measurement class is that bioelectrical impedance may vary depending on the hydration status of the individual, which means the underlying reading shifts with how hydrated a body is at that moment.
Is DXA the right answer for an individual then?
The guidance is careful in both directions. It calls imaging such as DXA more precise than the cheaper methods. In the same passage it says imaging is expensive, requires multiple blinded central readers to run in a trial, and may produce results that are not generalizable to the clinical care of patients. Whether any measurement is worth doing for a particular person is a question for that person's clinician.